6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications
Key Takeaways
Systemic menopausal hormone therapy (MHT) is FDA-approved and clinically indicated for moderate-to-severe vasomotor symptoms, prevention of postmenopausal osteoporosis in high-risk individuals, and management of hypoestrogenism in premature menopause or POI until age ~51.
The Timing Hypothesis establishes that initiating MHT within 10 years of menopause or before age 60 provides a favorable benefit-risk profile, lowering all-cause mortality and coronary heart disease, whereas late initiation (>10-20 years post-menopause or age >=60) increases risks of stroke and venous thromboembolism.
Transdermal 17-beta estradiol bypasses hepatic first-pass metabolism, does not increase clotting factors or sex hormone-binding globulin (SHBG), and carries minimal or no increased risk of venous thromboembolism (VTE) or ischemic stroke compared to oral formulations.
Endometrial protection is mandatory in all women with an intact uterus using systemic estrogen, requiring an adequate progestogen (e.g., micronized progesterone 100 mg daily or 200 mg cyclic x 12-14 days/month, or a 52-mg LNG-IUS) to prevent endometrial hyperplasia and adenocarcinoma.
Fezolinetant is a selective oral neurokinin 3 (NK3) receptor antagonist FDA-approved for moderate-to-severe vasomotor symptoms; it carries a boxed warning for liver injury and requires hepatic tests at baseline, monthly for 3 months, and at 6 and 9 months.
Indications for Systemic Menopausal Hormone Therapy (MHT)
Menopausal Hormone Therapy (MHT) is the most effective evidence-based pharmacotherapy for menopausal symptoms. Guidelines from The Menopause Society and ACOG establish four primary systemic indications:
- Bothersome Vasomotor Symptoms (VMS): Systemic estrogen reduces hot flash frequency by ~75% and severity by ~87%, simultaneously improving sleep fragmentation, mood, and quality of life.
- Prevention of Postmenopausal Osteoporosis: Estrogen decreases fractures across all skeletal sites by 30% to 40%. It is indicated for fracture prevention in at-risk women under age 60 or within 10 years of menopause.
- Hypoestrogenism in Premature Menopause / POI: Women experiencing premature menopause or POI before age 40 face accelerated cardiovascular, bone, and neurocognitive morbidity. Systemic MHT at replacement doses is strongly recommended until at least the median age of natural menopause (~51 years).
- Genitourinary Syndrome of Menopause (GSM): Treats vulvovaginal atrophy when present alongside systemic VMS; if GSM occurs in isolation, local vaginal estrogen is preferred.
The "Timing Hypothesis" & The Window of Opportunity
Clinical trials (including WHI sub-analyses, ELITE, and KEEPS) demonstrate that the benefit-to-risk balance of MHT depends on patient age and time elapsed since menopause:
| Clinical Parameter | Initiation <60 Years Old or <10 Years Post-Menopause | Initiation ≥60 Years Old or ≥10–20 Years Post-Menopause |
|---|---|---|
| Coronary Heart Disease | Decreased coronary calcification; reduced coronary heart disease events and mortality (RR ~0.70–0.80). | Increased coronary events via destabilization of existing fibroatheromatous plaques. |
| Ischemic Stroke | Low baseline absolute stroke risk; neutral or minimal excess events. | Statistically significant increase in absolute stroke incidence. |
| Venous Thromboembolism | Low absolute risk, particularly when using transdermal estradiol. | Substantially elevated absolute VTE and pulmonary embolism risk with oral regimens. |
| All-Cause Mortality | Significant reduction in all-cause mortality (RR ~0.70–0.85). | Neutral or slightly increased all-cause mortality. |
| Clinical Recommendation | Favorable benefit-risk profile; optimal window for initiation. | Unfavorable benefit-risk balance; initiation generally not recommended. |
Note
In November 2025 the FDA began removing the boxed warnings about cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy labels; the first six products were relabeled on February 12, 2026. The boxed warning about endometrial cancer with unopposed systemic estrogen in a patient with a uterus remains.
Estrogen Regimens & Delivery Routes: Oral vs. Transdermal
Selecting the route of estrogen administration is vital to optimizing cardiovascular and metabolic safety.
Oral Estrogens
Oral formulations include micronized 17-beta estradiol (0.5–2.0 mg daily) and conjugated equine estrogens (CEE 0.3–0.625 mg daily). Oral intake undergoes hepatic first-pass metabolism, inducing several adverse biochemical pathways:
- Prothrombotic Coagulation Factors: Upregulates prothrombin, factors VII and VIII, and prothrombin fragments, while decreasing antithrombin III, causing a 2- to 4-fold increase in venous thromboembolism (VTE) and stroke.
- Sex Hormone-Binding Globulin (SHBG): Hepatic induction raises SHBG, reducing circulating free androgens and potentially worsening libido.
- Inflammatory & Lipid Markers: Elevates serum triglycerides and high-sensitivity C-reactive protein (hs-CRP).
Transdermal Estrogens
Transdermal formulations (patches 0.025–0.1 mg/day, gels, sprays) deliver bioidentical 17-beta estradiol directly into systemic circulation, completely bypassing hepatic first-pass transit.
- Coagulation Neutrality: Does not induce prothrombotic clotting factors; conveys neutral or non-significant excess risks of VTE and ischemic stroke.
- Metabolic Stability: Preserves baseline levels of triglycerides, hs-CRP, and SHBG.
- Preferred Candidates: First-line choice for women with hypertension, obesity (BMI ≥30 kg/m²), hypertriglyceridemia, controlled diabetes, smoking history, or gallbladder disease.
Essential Endometrial Protection: Regimens & Formulations
Unopposed systemic estrogen drives continuous endometrial epithelial proliferation, inducing glandular atypia, hyperplasia, and a 4- to 8-fold increase in endometrial adenocarcinoma within 3 to 5 years.
Important
Mandatory Rule: Any woman with an intact uterus receiving systemic estrogen MUST receive concurrent progestogen therapy to ensure complete endometrial protection. Estrogen monotherapy is strictly contraindicated with an intact uterus and reserved solely for patients post-hysterectomy.
Progestogen Regimens
- Continuous-Combined Regimen: Daily estrogen with daily oral micronized progesterone (100 mg) or medroxyprogesterone acetate (MPA 2.5 mg). Induces endometrial atrophy and amenorrhea (following initial transient spotting).
- Cyclic (Sequential) Regimen: Daily estrogen with oral micronized progesterone (200 mg) or MPA (5–10 mg) taken for 12 to 14 consecutive days each month. Induces predictable scheduled withdrawal bleeding; optimal for perimenopausal women with irregular spontaneous menses.
- Levonorgestrel Intrauterine System (52-mg LNG-IUS): Delivers potent local endometrial suppression with negligible systemic absorption, concurrently providing contraception during perimenopause.
- Micronized Progesterone Benefits: Chemically identical to endogenous progesterone; conveys a lower association with breast cancer and fewer adverse mood/lipid effects than synthetic progestins (such as MPA).
Absolute Contraindications to MHT
Clinicians must screen for absolute contraindications before initiating MHT:
- Unexplained, undiagnosed abnormal vaginal bleeding (requires endometrial biopsy and transvaginal ultrasound to rule out malignancy first).
- Known, suspected, or history of breast cancer or other estrogen-dependent malignancies.
- Active or documented history of arterial thromboembolic disease (myocardial infarction, ischemic stroke, TIA).
- Active deep vein thrombosis (DVT) or pulmonary embolism (PE), or unprovoked VTE history.
- Active liver disease, acute liver injury, or significant chronic hepatic impairment.
- Known high-risk thrombophilia (homozygous Factor V Leiden, antiphospholipid syndrome).
- Known or suspected pregnancy.
Non-Hormonal Pharmacotherapy for Vasomotor Symptoms
Indicated for women with contraindications to estrogen (e.g., breast cancer survivors, thromboembolic history) or those declining hormones.
Fezolinetant (Veozah)
- Mechanism: Selective oral neurokinin 3 (NK3) receptor antagonist (45 mg once daily) that blocks neurokinin B on hypothalamic KNDy neurons, restoring thermoregulatory balance without hormonal or tissue-proliferative effects.
- Hepatic Monitoring: Serum transaminase elevations occur in 2% to 3% of patients. A December 2024 boxed warning for rare serious liver injury requires baseline hepatic tests (ALT, AST, alkaline phosphatase, bilirubin), then testing monthly for the first 3 months and at 6 and 9 months; stop the drug if signs of liver injury appear.
- Contraindications: Severe renal impairment (eGFR <30 mL/min/1.73 m²), cirrhosis, or concomitant use of moderate/strong CYP1A2 inhibitors (ciprofloxacin, fluvoxamine).
Elinzanetant (Lynkuet)
- Dual neurokinin-1/neurokinin-3 receptor antagonist approved by the FDA on October 24, 2025 for moderate-to-severe menopausal hot flashes. The dose is 120 mg (two 60 mg capsules) once daily at bedtime; sleepiness and fatigue are the main adverse effects, so counsel about driving and alcohol.
Centrally Acting Agents
- SSRIs and SNRIs: Paroxetine mesylate (7.5 mg daily; FDA-approved for VMS), venlafaxine XR (37.5–75 mg daily), desvenlafaxine (100 mg daily), and escitalopram (10–20 mg daily).
- Tamoxifen Drug Interaction: Paroxetine and fluoxetine are potent CYP2D6 inhibitors that block the bioactivation of tamoxifen into its active metabolite, endoxifen, increasing cancer recurrence. Venlafaxine or gabapentin is preferred in patients taking tamoxifen because neither significantly inhibits CYP2D6.
- Gabapentin: Alpha-2-delta calcium channel ligand (300–900 mg at bedtime); ideal for nocturnal hot flashes with sleep disruption.
- Clonidine: Alpha-2 adrenergic agonist (0.05–0.1 mg daily); modest efficacy, limited by dry mouth, hypotension, and sedation.
A 52-year-old female presents to the clinic with severe, disruptive hot flashes (10 to 12 episodes daily) and sleep disruption. Her last menstrual period was 8 months ago. She has an intact uterus. Her past medical history is unremarkable, with normal blood pressure, a body mass index of 23 kg/m², normal mammogram 2 months ago, and no personal or family history of thrombosis or breast cancer. Which menopausal hormone therapy regimen represents the most appropriate initial evidence-based management for this patient?
Transdermal 17-beta estradiol patch 0.05 mg/day combined with oral micronized progesterone 100 mg daily at bedtime.
Oral conjugated equine estrogens (CEE) 0.625 mg daily as monotherapy without progestogen.
Transdermal 17-beta estradiol patch 0.05 mg/day monotherapy accompanied by annual screening endometrial biopsies.
Oral 17-beta estradiol 1.0 mg daily combined with tamoxifen 20 mg daily.
A 55-year-old female with a history of stage I ER-positive, PR-positive invasive ductal breast cancer treated 3 years ago with lumpectomy, radiation, and current adjuvant tamoxifen presents with debilitating hot flashes occurring 12 to 14 times per day. She reports that non-pharmacologic lifestyle changes have failed to provide relief. Which pharmacologic regimen is the safest and most appropriate prescription for managing her vasomotor symptoms?
Low-dose transdermal estradiol patch (0.025 mg/day) combined with oral micronized progesterone.
Oral paroxetine 20 mg once daily.
Venlafaxine extended-release (XR) 37.5 to 75 mg orally once daily.
Oral conjugated equine estrogens (CEE) 0.3 mg daily.
A 53-year-old female with an intact uterus presents requesting hormone therapy for debilitating vasomotor symptoms that began 1 year ago. Her medical history is notable for class I obesity (BMI 32.4 kg/m²), well-controlled primary hypertension on lisinopril 10 mg daily, and fasting hypertriglyceridemia (265 mg/dL). She has no history of cardiovascular events or thromboembolism. When formulating a systemic hormone therapy regimen, why is transdermal 17-beta estradiol preferred over oral estradiol formulations for this patient?
Transdermal estradiol stimulates hepatic sex hormone-binding globulin (SHBG) synthesis to improve free androgen levels.
Transdermal estradiol bypasses hepatic first-pass metabolism, avoiding the upregulation of prothrombotic clotting factors and serum triglycerides.
Transdermal estradiol eliminates the requirement for concurrent progestogen endometrial protection in women with an intact uterus.
Transdermal estradiol is the only estrogen formulation approved for treating secondary hypertriglyceridemia.
Sections you finish are checked off in the contents.